These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 28920255)

  • 1. Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer.
    Wang HQ; Ren Y; Qian ZZ; Fu K; Zhang HL; Li W; Hou Y; Zhou SY; Hao XS; Xie CH
    Thorac Cancer; 2012 Feb; 3(1):72-78. PubMed ID: 28920255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nimotuzumab in combination with chemotherapy in patients with advanced non-small cell lung cancer].
    Li LF; Wang HQ; Liu XM; Zhang HL; Qiu LH; Qian ZZ; Li W
    Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):626-8. PubMed ID: 22325226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
    Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer.
    Zhao J; Zhuo M; Wang Z; Duan J; Wang Y; Wang S; An T; Wu M; Wang J
    Chin J Cancer Res; 2016 Feb; 28(1):12-8. PubMed ID: 27041923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical report of combined chemotherapy with gemcitabine plus cisplatin as first-line treatment to 79 cases of advanced non-small cell lung cancer].
    Lin L; Hao X; Li J; Wang Z; Wang Y; Wang H; Hu X; Zhang X
    Zhongguo Fei Ai Za Zhi; 2007 Dec; 10(6):513-9. PubMed ID: 21129311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
    Kim HR; Jang JS; Sun JM; Ahn MJ; Kim DW; Jung I; Lee KH; Kim JH; Lee DH; Kim SW; Cho BC
    Oncotarget; 2017 Feb; 8(9):15943-15951. PubMed ID: 27823977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.
    Cetina L; Crombet T; Jiménez-Lima R; Zapata S; Ramos M; Avila S; Coronel J; Charco E; Bojalil R; Astudillo H; Bazán B; Dueñas-González A
    Cancer Biol Ther; 2015; 16(5):684-9. PubMed ID: 25802932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer.
    Chen CH; Lin CM; Kao KC; Chang JW; Tsao TC
    Chang Gung Med J; 2007; 30(3):249-55. PubMed ID: 17760276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
    Hamada H; Irifune K; Ito R; Sakai K; Kadowaki T; Katayama H; Abe M; Shiode M; Nishimura K; Higaki J
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1235-9. PubMed ID: 17687204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in Non-Small Cell Lung Cancer.
    Kim YJ; Sohn JH; Kim C; Kim YT; Kim HJ; Ahn JB; Kim SK; Chang J; Yoo NC; Kim JH; Cho JY
    Cancer Res Treat; 2003 Aug; 35(4):294-8. PubMed ID: 26680950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.
    Pallis AG; Agelidou A; Papakotoulas P; Tsaroucha A; Agelidou M; Agelaki S; Androulakis N; Vamvakas L; Gerogianni A; Kotsakis A; Kentepozidis N; Georgoulias V
    Lung Cancer; 2006 May; 52(2):165-71. PubMed ID: 16563559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan.
    Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
    Lung Cancer; 2007 Jun; 56(3):363-9. PubMed ID: 17306906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer.
    Tas F; Sen F; Guney N; Keskin S; Camlica H
    Oncol Lett; 2013 May; 5(5):1699-1703. PubMed ID: 23761836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of gemcitabine and cisplatin as first-line therapy in advanced non-small-cell lung cancer.
    Lee NS; Byun JH; Bae SB; Kim CK; Lee KT; Park SK; Won JH; Hong DS; Park HS
    Cancer Res Treat; 2004 Jun; 36(3):173-7. PubMed ID: 20396540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma.
    Si X; Wu S; Wang H; Zhang X; Wang M; Zeng X; Zhang L
    Thorac Cancer; 2018 Aug; 9(8):1056-1061. PubMed ID: 29920955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study.
    Babu KG; Prabhash K; Vaid AK; Sirohi B; Diwakar RB; Rao R; Kar M; Malhotra H; Nag S; Goswami C; Raina V; Mohan R
    Onco Targets Ther; 2014; 7():1051-60. PubMed ID: 24966687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of nimotuzumab combined with chemoradiotherapy in Chinese patients with locally advanced cervical cancer.
    Chen YF; Tang WB; Pan XX; Wu CR; Cao Y; Yang W
    Onco Targets Ther; 2017; 10():4113-4119. PubMed ID: 28860820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.